North America Liver Disease Treatment Market Size, Share, Industry, Forecast and Outlook (2024-2031)

North America Liver Disease Treatment Market is segmented By Treatment Type (Antiviral Drugs, Immunosuppressants, Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy Drugs), By Disease Type (Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Liver Cancer, Genetic Disorder, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgery Centers, Others) – Share, Size, Outlook, and Opportunity Analysis,  2024-2031

Report Overview

The North America liver disease treatment market reached US$ 7.9 billion in 2023 and is expected to reach US$ 12.28 billion by 2031, growing at a CAGR of 5.8% during the forecast period 2024-2031.

The liver disease treatment market is expanding rapidly, driven by the increasing prevalence of liver disorders such as hepatitis, fatty liver disease, and cirrhosis. Factors such as rising alcohol intake, obesity rates, and viral infections all contribute to this trend, creating a greater need for appropriate treatment solutions. The industry offers a wide range of medicines, including antiviral drugs, immunosuppressants, and new gene therapies.

Recent advances in biotechnology and pharmaceuticals have fueled innovation, with many corporations investing in research and development of new medications. This includes medications that target specific pathways involved in liver disease progression, which raises the prospect of more tailored and effective treatments. Furthermore, the growing focus on preventative interventions and early diagnosis is altering market dynamics, with healthcare providers increasingly.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Increasing prevalence of liver diseases 

The rising prevalence of liver diseases propels the market growth. For instance, according to the American Liver Foundation, More than 100 million people in the U.S. have some form of liver disease. 4.5 million U.S. adults (1.8%) have been diagnosed with liver disease. But it is estimated that 80-100 million adults in the U.S. have fatty liver disease and many do not know they have it. If left untreated, liver disease can lead to liver failure and liver cancer. 

Cirrhosis increases the risk of stroke. Stroke incidence was 2.17% (95% CI, 1.99%-2.36%) per year in patients with cirrhosis and 1.11% (95% CI, 1.10%-1.11%) per year in patients without cirrhosis. Rates of liver cirrhosis deaths have been consistently higher for Black/African American men and women than their White counterparts for many years. The number of deaths due to chronic liver disease and cirrhosis is 54,803. The number of deaths due to chronic liver disease and cirrhosis per 100,000 population is 16.4.

Between 800,000 and 1.4 million people in the United States are living with chronic hepatitis B infection, according to the Centers for Disease Control and Prevention (CDC). There are approximately 43,000 new hepatitis B cases each year in the U.S. Alcohol remains the second most common cause of liver cirrhosis after hepatitis C virus (HCV) infection in the United States, contributing to approximately 20% to 25% of cases of liver cirrhosis. 

Restraints

Factors such as high costs associated with the treatment and stringent regulatory requirements for the approval of new treatments are expected to hamper the market. The higher costs of drugs that are associated with the treatment of various liver diseases affect the affordability for many people and this acts as a restraint to the North America liver disease treatment market. 

Market Segment Analysis

The North America liver disease treatment market is segmented based on disease type, treatment type, and end-user.

The segment non-alcoholic fatty liver disease accounted for approximately 42.7% of the North America liver disease treatment market share.

The non-alcoholic fatty liver disease segment is expected to hold the largest market share over the forecast period. In this segment, the increasing prevalence and recent treatment approvals would drive this market. 

Nonalcoholic fatty liver disease (NAFLD) is a condition in which excess fat builds up in the liver. This buildup of fat is not caused by heavy alcohol use. When heavy alcohol use causes fat to build up in the liver, this condition is called alcohol-associated liver disease. Two types of NAFLD are nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). People typically develop one type of NAFLD or the other, although sometimes people with one form are later diagnosed with the other form of NAFLD.

For instance, according to the American Liver Foundation, NAFLD is the most common chronic liver condition in the United States. It’s estimated that about 25 percent of adults in the U.S. have NAFLD. Of those with NAFLD, about 20 percent have NASH (5% of adults in the U.S.). Most people with NAFLD have simply fatty liver. According to the National Institute of Diabetes and Digestive and Kidney Diseases, NAFLD is one of the most common causes of liver disease in the United States. The majority of people with NAFLD have NAFL. Only a small number of people with NAFLD have NASH. Experts estimate about 24% of U.S. adults have NAFLD and about 1.5% to 6.5% of U.S. adults have NASH.

Market Segmentation

By Disease Type

• Hepatitis 
• Autoimmune Diseases
• Non-Alcoholic Fatty Liver Disease
• Liver Cancer
• Genetic Disorder
• Others 

By Treatment Type

• Antiviral Drugs  
• Sofosbuvir
• Ombitasvir 
• Immunosuppressants
• Vaccines
• Hepatitis B vaccine
• Hepatitis A vaccine
• Combined hepatitis A and B vaccine 
• Immunoglobulins
• Corticosteroids
• Prednisone 
• Targeted Therapy
• Sorafenib 
• Regorafenib  
• Chemotherapy Drugs
• Nivolumab
• Pembrolizumab

By End-User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Market Competitive Landscape

The major global players in the North America Pacific liver disease treatment market include Pfizer Inc., AbbVie Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche, Takeda Pharmaceutical Company Limited Ltd, Novo Nordisk A/S, Eli Lilly and Company, Bristol-Myers Squibb Company, Amgen Inc., Gilead Sciences Inc. among others.

Key Developments

• In October 2024, the U.S. Food and Drug Administration approved the use of sound waves to break down tumors, a technique called histotripsy in humans for liver treatment. At the University of Michigan, histotripsy offers a promising alternative to cancer treatments such as surgery, radiation, and chemotherapy. 

Why Purchase the Report?

• To visualize the North America liver disease treatment market segmentation based on disease type, treatment type, and end-user as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of North America liver disease treatment market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The North America liver disease treatment market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies